Trials / Completed
CompletedNCT04135521
Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer
Far Eastern Memorial Hospital
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- Far Eastern Memorial Hospital · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with advanced stage ovarian cancer.
Detailed description
Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II\~IV), who had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were included in the study. Patient characteristics, any treatment related side-effects (peri-operative and post-operative complications, chemotherapy related adverse events), treatment response (complete or partial response, stable disease or progressive disease), post-treatment surveillance (disease status: disease-free, recurrence or cancer-related death) will be recorded. Univariate and multivariate logistic regression analysis will be employed to evaluate the survival benefit of the two different chemotherapy methods.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Intraperitoneal chemotherapy | Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy |
Timeline
- Start date
- 2019-10-28
- Primary completion
- 2020-03-31
- Completion
- 2020-03-31
- First posted
- 2019-10-22
- Last updated
- 2020-06-29
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04135521. Inclusion in this directory is not an endorsement.